Pharmacological activation of Peroxisome proliferator-activated receptor improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice

Hormone and Metabolic Research

Volumn 43, Issue 9, 2011, Pages 631-635

  Wu, H T ^a   Chen, C T ^b   Cheng, K C ^c   Li, Y X ^c   Yeh, C H ^d   Cheng, J T ^a,b,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

diabetes; hepatic steatosis; high fat diet; insulin resistance; peroxisome proliferator activated receptor

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; GLUCOSE; GLYCOGEN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FATTY LIVER; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GLYCOGEN LIVER LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; PHENOXYACETATES; PPAR DELTA;

MUS;

EID: 80051795701     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1280781     Document Type: Article

References (31)

1. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology: 2002; 123 1705 1725 (Pubitemid 35231670)
2. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol: 2002; 34 255 262 (Pubitemid 34177381)
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med: 2002; 346 1221 1231
4. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med: 1999; 107 450 455 (Pubitemid 29528333)
5. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem: 2004; 279 32345 32353 (Pubitemid 39014687)
6. Kim JK, Fillmore JJ, Chen Y, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA: 2001; 98 7522 7527 (Pubitemid 32567981)
7. Schupp M, Lazar MA. Endogenous ligands for nuclear receptors: digging deeper. J Biol Chem 285 4040940415
8. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev: 1999; 20 649 688 (Pubitemid 30650602)
9. Cowherd RM, Lyle RE, McGehee RE Jr. Molecular regulation of adipocyte differentiation. Semin Cell Dev Biol: 1999; 10 3 10 (Pubitemid 129505533)
10. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med: 2008; 5 542 553
11. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta: 2007; 1771 972 982
12. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem: 2011; 21 781 792
13. Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther: 2008; 6 1319 1330
14. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol: 2011; 10 365 376
15. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature: 2007; 447 1116 1120 (Pubitemid 47014427)
16. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord: 2003; 27 03 S17 S21 (Pubitemid 38019182)
17. Choi KC, Lee SY, Yoo HJ, Ryu OH, Lee KW, Kim SM, Baik SH, Choi KM. Effect of PPAR-delta agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes. Biochem Biophys Res Commun: 2007; 357 62 67 (Pubitemid 46574500)
18. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology: 2001; 142 4195 4202 (Pubitemid 32907045)
19. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong J, Heirman C, Quartier E, Schuit F, Wahli W, Geerts A. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology: 2003; 124 184 201 (Pubitemid 36055351)
20. Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, Duan K, Ouh J, Wands JR. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol: 2009; 50 1192 1201
21. Sasaki Y, Shimada T, Iizuka S, Suzuki W, Makihara H, Teraoka R, Tsuneyama K, Hokao R, Aburada M. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. Eur J Pharmacol: 2011; May 1 [Epub ahead of print]
22. de la Monte SM, Pang M, Chaudhry R, Duan K, Longato L, Carter J, Ouh J, Wands JR. Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. Hepatol Res: 2011; 41 386 398
23. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell: 2003; 113 159 170 (Pubitemid 36514968)
24. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med: 2004; 10 1245 1250 (Pubitemid 39540443)
25. Labonte ED, Pfluger PT, Cash JG, Kuhel DG, Roja JC, Magness DP, Jandacek RJ, Tschp MH, Hui DY. Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity. FASEB J: 2011; 24 2516 2524
26. Qin X, Xie X, Fan Y, Tian J, Guan Y, Wang X, Zhu Y, Wang N. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology: 2008; 48 432 441
27. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem: 1999; 274 6718 6725 (Pubitemid 29111093)
28. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA: 2006; 103 3444 3449 (Pubitemid 43346488)
29. Wu HT, Chang CK, Tsao CW, Wen YJ, Ling SM, Cheng KC, Chang CJ, Cheng JT. Insulin resistance without obesity induced by cotton pellet granuloma in mice. Lab Invest: 2009; 89 362 369
30. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, Yamauchi T, Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, Kadowaki T. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem: 2006; 281 26602 26614 (Pubitemid 44401869)
31. Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoji M, Wands JR, de la Monte SM. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol: 2003; 38 615 622 (Pubitemid 36560646)